Tag Archives: Optimi Health

Naturally-Derived 5 mg Psilocybin Capsules Mark the Company’s Second Drug in Market Under Australia’s Authorised Prescriber Scheme Vancouver, British Columbia–(Newsfile Corp. – February 19, 2026) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today announced …

The Company is now recognized by the U.S. FDA to support the cross-border supply of GMP MDMA and psilocybin to authorized entities in the United States. Vancouver, British Columbia–(Newsfile Corp. – May 5, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a manufacturer …

Vancouver, British Columbia–(Newsfile Corp. – March 12, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a GMP-compliant, Health Canada-licensed manufacturer specializing in botanical psilocybin and MDMA, is pleased to provide the following corporate update, highlighting key regulatory milestones, clinical trial progress, and expanded …

Over 4,000 GMP Capsules Ready to Support PTSD Treatment in Australia, Israel, and Canada Vancouver, British Columbia–(Newsfile Corp. – January 29, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and supply natural, GMP-grade psilocybin …

Vancouver, British Columbia–(Newsfile Corp. – January 28, 2025) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company”), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, announces it has closed the second and final tranche (the “Second Tranche”) of its …